About Raptor Pharma
Raptor Pharma is a Healthcare company based in Novato (United States) founded in 2005, and was acquired by Horizon Therapeutics in September 2016. Small molecule therapeutics for rare diseases are developed. The company has 128 employees. Raptor Pharma has completed 1 acquisition, including TorreyPines Therapeutics. Raptor Pharma offers products and services including Biologic Medicines, DNA Encoded Libraries, ATOMIC Model, and Omics Research. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is RAPTOR PHARMACEUTICALS INC. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Raptor Pharma was founded in 2005 and is based in Novato, United States. Focus is placed on the development of small molecule therapeutics targeting rare diseases within the pharmaceutical sector. Two products have been commercialized: PROCYSBI delayed-release capsules for nephropathic cystinosis management and QUINSAIR for chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients. Active clinical programs are maintained in Huntingtons disease, Leigh syndrome, and other mitochondrial disorders.
- Headquarters Novato, United States
- Employees 128
- Stage Acquired
- SectorsHealthcare
- Website raptorpharma.com
- Social LinkedIn
- Acquired by Horizon Therapeutics (Sep 2016)
- Legal Name Raptor Pharmaceuticals Inc
- Latest Funding Round$75M (USD), Post-IPO
Sep 2015
- InvestorsHorizon Therapeutics
& 1 more
- Employee Count128
- Investments & Acquisitions
- Acquired byHorizon Therapeutics
(Sep 2016)
Products & Services of Raptor Pharma
Raptor Pharma offers a comprehensive portfolio of products and services, including Biologic Medicines, DNA Encoded Libraries, ATOMIC Model, and Omics Research.
Treatments for serious diseases using biologic methods
Platform for screening compounds to develop new therapies
Machine learning system to accelerate clinical trials
Approach for gaining insights into disease biology
Funding Insights of Raptor Pharma
- Total Rounds 8
- Last Round Post-IPO — $75M
- First Round $10M
(Jun 2008)
- Investors Count 1
All 8 funding rounds of Raptor Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2015 | $75M | Post-IPO | – | – | – |
| Jul 2014 | $70M | Post-IPO | – | – | |
| Dec 2012 | $50M | Debt – Conventional | – | – | |
| Aug 2010 | $15.06M | Post-IPO | – | – | – |
| Dec 2009 | $7.5M | Post-IPO | – | – | – |
| Sep 2009 | $2.39M | Post-IPO | – | – | – |
| Aug 2009 | $5M | Post-IPO | – | – | – |
| Jun 2008 | $10M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Raptor Pharma
Raptor Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Horizon Therapeutics and HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
Developer of drugs for treating rare and autoimmune diseases | 2008 | horizontherapeutics.com | Dublin, Ireland |
Investor details for Raptor Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Raptor Pharma
Raptor Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include TorreyPines Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule drugs for CNS disorders are developed. | torreypinestherapeutics.com | San Diego, United States | 2000 | Jul 2009 | •••• |
Complete acquisition details for Raptor Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Raptor Pharma
5 dated milestones of Raptor Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Raptor Pharma is founded.
- Funding First funding round of $10.0M.
- Acquisition Acquires TorreyPines Therapeutics.
- Funding Latest funding round, Post-IPO, of $75.0M.
- Exit Acquired by Horizon Therapeutics.
Competitors of Raptor Pharma
Raptor Pharma has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Raptor Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Raptor Pharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Raptor Pharma
Raptor Pharma was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Raptor Pharma is headquartered in Novato, United States. It is registered at Novato, California, United States.
Raptor Pharma has 128 employees.
Raptor Pharma was founded in 2005 and is based in Novato, United States. Focus is placed on the development of small molecule therapeutics targeting rare diseases within the pharmaceutical sector. Two products have been commercialized: PROCYSBI delayed-release capsules for nephropathic cystinosis management and QUINSAIR for chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis patients. Active clinical programs are maintained in Huntingtons disease, Leigh syndrome, and other mitochondrial disorders.
Raptor Pharma's top competitors include BridgeBio, Forge Biologics and Insitro.
Raptor Pharma offers Biologic Medicines, DNA Encoded Libraries, ATOMIC Model, and Omics Research.
Raptor Pharma has made 1 acquisition, including TorreyPines Therapeutics.
Raptor Pharma has 2 investors. Key investors include Horizon Therapeutics, and HealthCare Royalty Partners.
Raptor Pharma operates through Raptor Pharmaceuticals Inc.
Yes. Raptor Pharma was acquired by Horizon Therapeutics in September 2016.